Topic Hub
22 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 22 of 22 clinical reviews.
A clinical deep-dive into retatrutide use after bariatric surgery, covering pharmacology, post-surgical weight regain, dosing considerations, safety signals, and the latest Phase 2 trial data.
Read clinical reviewA physician-reviewed guide to retatrutide autoimmune disease considerations, covering GIP/GLP-1/glucagon receptor pharmacology, immune-modulation signals, phase 2 trial safety data, and clinical decision-making for patients with autoimmune conditions.
Read clinical reviewHow does retatrutide affect appetite and cravings? A deep clinical review of the triple-agonist mechanism, Phase 2 trial data, and practical implications for patients and prescribers.
Read clinical reviewA deep review of how retatrutide affects bone mineral density, fracture risk, and bone turnover markers, based on Phase 2 trial data and the mechanistic science of triple-receptor agonism.
Read clinical reviewA physician-level review of retatrutide's cancer risk signals from Phase 2 trial data, rodent carcinogenicity studies, and GLP-1/GIP/glucagon receptor biology, with citations to primary literature.
Read clinical reviewA physician-reviewed deep dive into how retatrutide, the triple GIP/GLP-1/glucagon receptor agonist, may affect cognitive function, neuroinflammation, and brain metabolism based on current Phase 2 data and mechanistic research.
Read clinical reviewA physician-reviewed comparison of compounded retatrutide versus the eventual branded formulation, covering Phase 2 efficacy data, safety signals, regulatory status, and what patients and clinicians need to know before choosing.
Read clinical reviewA GRADE-level analysis of retatrutide's evidence base, from the Phase 2 NEJM 2023 trial through ongoing Phase 3 development. Covers efficacy, safety, mechanism, and what clinicians need to know now.
Read clinical reviewA physician-reviewed breakdown of every hair and skin change reported with retatrutide in the NEJM 2023 phase 2 trial, including telogen effluvium risk, skin laxity, and what patients can do.
Read clinical reviewA physician-reviewed deep dive into how retatrutide, the triple GIP/GLP-1/glucagon receptor agonist, affects mood, anxiety, depression risk, and neuropsychiatric safety based on Phase 2 trial data and mechanistic research.
Read clinical reviewA clinician-level breakdown of how retatrutide's triple agonist mechanism drives metabolic rate, fat oxidation, and thermogenesis, with full citations from Jastreboff et al. 2023 and related primary literature.
Read clinical reviewA physician-reviewed deep dive into retatrutide microdosing protocols, Phase 2 trial data, dose-escalation schedules, and what triple-agonist pharmacology means for weight loss in 2024.
Read clinical reviewA clinician-level review of retatrutide muscle preservation strategies, covering resistance training protocols, protein targets, and adjunct therapies based on Phase 2 trial data and current exercise physiology evidence.
Read clinical reviewWhy weight loss stalls on retatrutide, what the phase 2 data says about non-responders, and the clinical steps a provider can take to restart progress.
Read clinical reviewRetatrutide rebound weight regain after stopping mirrors GLP-1/GIP/glucagon triple-agonist discontinuation data. Learn what Phase 2 evidence, mechanistic data, and clinical protocol guidance say about managing off-drug rebound.
Read clinical reviewA comprehensive, physician-reviewed analysis of retatrutide's effects on kidney function, including phase 2 trial data, mechanistic pathways, and what patients with CKD or at renal risk should know.
Read clinical reviewA clinician-level guide to retatrutide seasonal use considerations, covering heat stability, appetite fluctuations, activity-dependent dosing, and key Phase 2 data from Jastreboff et al. 2023.
Read clinical reviewA physician-level review of how retatrutide, the triple GIP/GLP-1/glucagon receptor agonist, affects sexual function in men and women, drawing on Phase 2 trial data, mechanistic evidence, and emerging clinical context.
Read clinical reviewRetatrutide, a GIP/GLP-1/glucagon triple agonist, produces 24.2% body-weight loss at 48 weeks. This article explains how that degree of fat loss, plus direct receptor activity, reshapes sleep architecture, OSA severity, slow-wave sleep, and REM patterns.
Read clinical reviewA clinician-level guide to managing retatrutide dosing during travel, timezone changes, and schedule disruptions, based on Phase 2 trial data and GLP-1/GIP/glucagon pharmacokinetics.
Read clinical reviewA clinician-level guide to safely restarting retatrutide after acute illness, covering dose de-escalation protocols, monitoring parameters, and evidence from the Jastreboff et al. Phase 2 trial.
Read clinical reviewA week-by-week clinical breakdown of retatrutide's first month: doses, side effects, weight loss timeline, and what the Phase 2 NEJM 2023 trial data actually show.
Read clinical review